Literature DB >> 26824369

The Simpson grading revisited: aggressive surgery and its place in modern meningioma management.

Konstantinos Gousias1,2, Johannes Schramm1, Matthias Simon1.   

Abstract

OBJECTIVE Recent advances in radiotherapy and neuroimaging have called into question the traditional role of aggressive resections in patients with meningiomas. In the present study the authors reviewed their institutional experience with a policy based on maximal safe resections for meningiomas, and they analyzed the impact of the degree of resection on functional outcome and progression-free survival (PFS). METHODS The authors retrospectively analyzed 901 consecutive patients with primary meningiomas (716 WHO Grade I, 174 Grade II, and 11 Grade III) who underwent resections at the University Hospital of Bonn between 1996 and 2008. Clinical and treatment parameters as well as tumor characteristics were analyzed using standard statistical methods. RESULTS The median follow-up was 62 months. PFS rates at 5 and 10 years were 92.6% and 86.0%, respectively. Younger age, higher preoperative Karnofsky Performance Scale (KPS) score, and convexity tumor location, but not the degree of resection, were identified as independent predictors of a good functional outcome (defined as KPS Score 90-100). Independent predictors of PFS were degree of resection (Simpson Grade I vs II vs III vs IV), MIB-1 index (< 5% vs 5%-10% vs >10%), histological grade (WHO I vs II vs III), tumor size (≤ 6 vs > 6 cm), tumor multiplicity, and location. A Simpson Grade II rather than Grade I resection more than doubled the risk of recurrence at 10 years in the overall series (18.8% vs 8.5%). The impact of aggressive resections was much stronger in higher grade meningiomas. CONCLUSIONS A policy of maximal safe resections for meningiomas prolongs PFS and is not associated with increased morbidity.

Entities:  

Keywords:  KPS = Karnofsky Performance Scale; OS = overall survival; PFS = progression-free survival; Simpson grade of resection; non–skull base meningioma; oncology; recurrence; skull base meningioma

Mesh:

Year:  2016        PMID: 26824369     DOI: 10.3171/2015.9.JNS15754

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  44 in total

Review 1.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

2.  Real-time in vivo kinetics of protoporphyrin IX after administration of 5-aminolevulinic acid in meningiomas and comparative analyses with glioblastomas.

Authors:  Sadahiro Kaneko; Benjamin Brokinkel; Eric Suero Molina; Nils Warneke; Markus Holling; Eva Christina Bunk; Katharina Hess; Volker Senner; Werner Paulus; Walter Stummer
Journal:  Acta Neurochir (Wien)       Date:  2020-05-02       Impact factor: 2.216

3.  Risk of Developing Postoperative Deficits Based on Tumor Location after Surgical Resection of an Intracranial Meningioma.

Authors:  Jeff S Ehresman; Tomas Garzon-Muvdi; Davis Rogers; Michael Lim; Gary L Gallia; Jon Weingart; Henry Brem; Chetan Bettegowda; Kaisorn L Chaichana
Journal:  J Neurol Surg B Skull Base       Date:  2018-07-17

4.  Management of pediatric CNS meningiomas: CCHE-57357 experience in 39 cases.

Authors:  Mohamed A El Beltagy; Abd Elrahman Enayet; Mostafa M E Atteya; Mohamed Reda; Amal Refaat; Hala Taha; Soha Ahmed; Amal Abdelaziz
Journal:  Childs Nerv Syst       Date:  2019-05-24       Impact factor: 1.475

5.  WHO grade I meningiomas: classification-tree for prognostic factors of survival.

Authors:  Jean-Michel Lemée; Holger Joswig; Michele Da Broi; Marco Vincenzo Corniola; David Scheie; Karl Schaller; Eirik Helseth; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2019-06-10       Impact factor: 3.042

Review 6.  Diagnostic challenges in meningioma.

Authors:  Martha Nowosielski; Norbert Galldiks; Sarah Iglseder; Philipp Kickingereder; Andreas von Deimling; Martin Bendszus; Wolfgang Wick; Felix Sahm
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

7.  WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.

Authors:  Anne Ressel; Susanne Fichte; Michael Brodhun; Steffen K Rosahl; Ruediger Gerlach
Journal:  J Neurooncol       Date:  2019-10-01       Impact factor: 4.130

8.  5-ALA kinetics in meningiomas: analysis of tumor fluorescence and PpIX metabolism in vitro and comparative analyses with high-grade gliomas.

Authors:  Eva Christine Bunk; Andrea Wagner; Walter Stummer; Volker Senner; Benjamin Brokinkel
Journal:  J Neurooncol       Date:  2021-01-03       Impact factor: 4.130

9.  Preoperative Embolization for Skull Base Meningiomas.

Authors:  Kensuke Suzuki; Masaya Nagaishi; Yoshiyuki Matsumoto; Yoshiko Fujii; Yuki Inoue; Yoshiki Sugiura; Koji Hirata; Ryotaro Suzuki; Yosuke Kawamura; Ryuta Nakae; Yoshihiro Tanaka; Akio Hyodo
Journal:  J Neurol Surg B Skull Base       Date:  2017-02-15

10.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.